Skip to main content
ALT
NASDAQ Life Sciences

Altimmune Q3 Loss Widens to $31.6M as MASH Phase 3 Spending Ramps; $494.9M Liquidity

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.649
Mkt Cap
$313.173M
52W Low
$1.6
52W High
$6.44
52W Position info
3.1% above low
Off High info
74% below high
Rel. Volume info
3.1× avg
Market data snapshot near publication time

ALT is trading near its 52-week low of $1.6 (3.1% above the low) on elevated volume (3.1× avg).

Summary

Altimmune's Q3 loss widened to $31.6 million ($0.15/share) on a 81% R&D jump, but $494.9 million of cash and investments plus the $10.0 million Hercules tranche keep the MASH Phase 3 program funded past twelve months. The April 2026 offering left 75 million warrants at a $3.00 strike outstanding.


Key Events · Earnings and Guidance · ALT

  • Q3 Loss Widens on Trial Spending

    Net loss of $31.6 million ($0.15/share) versus $19.0 million a year ago, driven by R&D of $27.0 million (up 81%) and G&A of $8.7 million (up 47%).

  • Liquidity of $494.9 Million

    $28.9 million cash, $236.2 million short-term investments and $214.8 million long-term investments at September 30, 2026; management says this funds operations for at least twelve months.

  • Hercules Tranche Three Drawn

    On October 27, 2026 the company drew $10.0 million of Tranche Three, extending the interest-only period to June 1, 2028 and requiring qualified cash of at least 60% of term loan principal.

  • 75 Million Warrants Overhang

    April 2026 offering left 75,000,000 common stock warrants at a $3.00 strike plus 10,750,000 pre-funded warrants outstanding; full cash exercise would raise $225 million.


Analysis · ALT · Life Sciences

The Q3 loss of $31.6 million ($0.15/share) came in well above the $25.48 million consensus as R&D jumped 81% to $27.0 million on the PERFORMA Phase 3 MASH trial and the RESTORE ALD trial. More important than the P&L is the balance sheet: $494.9 million of cash and investments ($28.9M cash, $236.2M short-term, $214.8M long-term) funds operations for at least twelve months, and the October 27 draw of the $10.0 million Hercules Tranche Three pushed the interest-only period out to June 1, 2028. Against that, nine-month operating burn of $82.9 million is up $34.8 million year over year, and the April 2026 offering left 75,000,000 common warrants at a $3.00 strike outstanding — roughly 39% of the 194.5 million shares outstanding — a large overhang that only becomes cash if the stock more than doubles from today's $1.65.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALT was trading at $1.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $313.2M. The 52-week trading range was $1.60 to $6.44. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALT - Latest Insights

ALT
Nov 12, 2026, 7:38 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $1.65 info
Change: -$0.2656 (-14%) info
Market Cap: $313.173M info
ALT
Nov 09, 2026, 12:30 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.14
Real-time Price: $1.65 info
Change: -$0.4856 (-23%) info
Market Cap: $313.173M info
ALT
Aug 12, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.96
Real-time Price: $1.65 info
Change: -$1.31 (-44%) info
Market Cap: $313.173M info
ALT
Aug 12, 2026, 7:43 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.06
Real-time Price: $1.65 info
Change: -$1.41 (-46%) info
Market Cap: $313.173M info
ALT
Aug 12, 2026, 7:33 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.01
Real-time Price: $1.65 info
Change: -$1.36 (-45%) info
Market Cap: $313.173M info